James N. Butera

1.7k total citations
55 papers, 1.2k citations indexed

About

James N. Butera is a scholar working on Pathology and Forensic Medicine, Hematology and Neurology. According to data from OpenAlex, James N. Butera has authored 55 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Pathology and Forensic Medicine, 15 papers in Hematology and 14 papers in Neurology. Recurrent topics in James N. Butera's work include Lymphoma Diagnosis and Treatment (22 papers), CNS Lymphoma Diagnosis and Treatment (12 papers) and Viral-associated cancers and disorders (10 papers). James N. Butera is often cited by papers focused on Lymphoma Diagnosis and Treatment (22 papers), CNS Lymphoma Diagnosis and Treatment (12 papers) and Viral-associated cancers and disorders (10 papers). James N. Butera collaborates with scholars based in United States, Peru and Croatia. James N. Butera's co-authors include Jorge J. Castillo, Eric S. Winer, Cannon Milani, Gerald A. Colvin, Dariusz Stachurski, Kimberly Perez, Brady Beltrán, Diana O. Treaba, Roberto N. Miranda and Anthony Mega and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

James N. Butera

49 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
James N. Butera United States 20 638 545 172 165 165 55 1.2k
Michele Bibas Italy 17 648 1.0× 500 0.9× 101 0.6× 124 0.8× 148 0.9× 33 1.0k
Glen Kennedy Australia 21 385 0.6× 287 0.5× 483 2.8× 217 1.3× 128 0.8× 115 1.4k
Nascimento Costa Portugal 15 233 0.4× 218 0.4× 219 1.3× 77 0.5× 82 0.5× 49 981
Juan‐Manuel Sancho Spain 23 807 1.3× 821 1.5× 363 2.1× 539 3.3× 431 2.6× 162 1.8k
Silvia Park South Korea 21 581 0.9× 260 0.5× 650 3.8× 203 1.2× 90 0.5× 163 1.5k
U Hess Switzerland 17 344 0.5× 385 0.7× 246 1.4× 308 1.9× 67 0.4× 46 955
Cynthia Rutherford United States 18 264 0.4× 201 0.4× 326 1.9× 210 1.3× 85 0.5× 35 1.1k
Ariella Kelman United States 14 231 0.4× 277 0.5× 322 1.9× 261 1.6× 93 0.6× 16 1.7k
Vivek Kumar United States 16 733 1.1× 205 0.4× 99 0.6× 118 0.7× 55 0.3× 63 1.1k
Netanel A. Horowitz Israel 17 429 0.7× 229 0.4× 215 1.3× 154 0.9× 102 0.6× 77 1.0k

Countries citing papers authored by James N. Butera

Since Specialization
Citations

This map shows the geographic impact of James N. Butera's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James N. Butera with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James N. Butera more than expected).

Fields of papers citing papers by James N. Butera

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James N. Butera. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James N. Butera. The network helps show where James N. Butera may publish in the future.

Co-authorship network of co-authors of James N. Butera

This figure shows the co-authorship network connecting the top 25 collaborators of James N. Butera. A scholar is included among the top collaborators of James N. Butera based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James N. Butera. James N. Butera is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Olszewski, Adam J., Anna Chorzalska, Diana O. Treaba, et al.. (2019). Tumor-Specific Cell-Free DNA (cfDNA) in the Cerebrospinal Fluid (CSF) Detects Cytologically Occult Central Nervous System (CNS) Involvement in Aggressive Lymphomas. Blood. 134(Supplement_1). 2800–2800. 1 indexed citations
3.
Fisch, Adam S., Florian J. Fintelmann, Henning A. Gaissert, et al.. (2019). Systemic Amyloidosis Mimicking Lung Cancer. American Journal of Respiratory and Critical Care Medicine. 201(1). 107–108. 3 indexed citations
4.
Olszewski, Adam J., Anna Chorzalska, Annette S. Kim, et al.. (2018). Recipients of Myelotoxic Chemotherapy Have Increased Prevalence of Clonal Hematopoiesis of Indeterminate Potential (CHIP) with a Typical Distribution of Chip-Associated Mutations. Blood. 132(Supplement 1). 3841–3841. 2 indexed citations
5.
Ouseph, Madhu M., James N. Butera, Rogers C. Griffith, Dariusz Stachurski, & Diana O. Treaba. (2016). Persistent eosinophilia in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and TP53 deletion is a potential predictor of variant Richter’s transformation. Annals of Pathology and Laboratory Medicine. 3(4). 1 indexed citations
6.
Ha, Austin Y., Patrick P. Gleason, Jonathan Winkler, et al.. (2016). Cryoglobulinemic membranoproliferative glomerulonephritis associated with mucosaassociated lymphoid tissue lymphoma treated with rituximab. PubMed. 4. 1–4. 2 indexed citations
7.
Butera, James N., et al.. (2016). TAFRO Syndrome Associated with EBV and Successful Triple Therapy Treatment: Case Report and Review of the Literature. SHILAP Revista de lepidopterología. 2016. 1–7. 26 indexed citations
8.
Connell, Nathan T. & James N. Butera. (2015). Attending Physician Attitudes Toward Choice of Oral Anticoagulant for the Treatment of Venous Thromboembolism.. PubMed. 98(7). 32–6. 5 indexed citations
9.
Castillo, Jorge J., Natalie Sinclair, Brady Beltrán, et al.. (2013). Similar outcomes in Asian and Western patients with diffuse large B-cell lymphoma treated with R-CHOP. Leukemia Research. 37(4). 386–391. 7 indexed citations
10.
Reagan, John L., Loren D. Fast, Howard Safran, et al.. (2013). Cellular immunotherapy for refractory hematological malignancies. Journal of Translational Medicine. 11(1). 150–150. 21 indexed citations
11.
Butera, James N., et al.. (2012). Spontaneous regression of chronic lymphocytic leukemia to a monoclonal B-lymphocytosis or to a normal phenotype. Leukemia & lymphoma. 54(8). 1647–1651. 8 indexed citations
12.
Beltrán, Brady, Jorge J. Castillo, Domingo Morales, et al.. (2011). EBV‐positive diffuse large B‐cell lymphoma of the elderly: A case series from Peru. American Journal of Hematology. 86(8). 663–667. 56 indexed citations
13.
Castillo, Jorge J., Eric S. Winer, Dariusz Stachurski, et al.. (2011). HIV-Negative Plasmablastic Lymphoma: Not in the Mouth. Clinical Lymphoma Myeloma & Leukemia. 11(2). 185–189. 74 indexed citations
14.
Morales, Domingo, Brady Beltrán, Fernando Hurtado de Mendoza, et al.. (2009). Epstein–Barr virus as a prognostic factor inde novonodal diffuse large B-cell lymphoma. Leukemia & lymphoma. 51(1). 66–72. 41 indexed citations
15.
Butera, James N., et al.. (2009). Acute myelogenous leukemia. Experimental Hematology. 37(6). 649–658. 151 indexed citations
16.
Milani, Cannon, Maria Constantinou, David Berz, James N. Butera, & Gerald A. Colvin. (2008). Left sided inferior vena cava duplication and venous thromboembolism: case report and review of literature. Journal of Hematology & Oncology. 1(1). 24–24. 43 indexed citations
17.
18.
Butera, James N., et al.. (2007). Are we training our fellows adequately in delivering bad news to patients? A survey of hematology/oncology program directors. Journal of Clinical Oncology. 25(18_suppl). 9023–9023. 2 indexed citations
19.
Tirado, Carlos A, Aurelia Meloni‐Ehrig, JoAnn C. Kelly, et al.. (2006). Dicentric (17;20)(p11.2;q11.2): an uncommon cytogenetic abnormality in myeloid malignancies. Cancer Genetics and Cytogenetics. 170(1). 61–64.
20.
Barnett, Janine, et al.. (2005). Lack of bleeding in patients with severe factor VII deficiency. American Journal of Hematology. 78(2). 134–137. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Michele Bibas Breakdown of academic impact, for papers by Glen Kennedy Breakdown of academic impact, for papers by Nascimento Costa Breakdown of academic impact, for papers by Juan‐Manuel Sancho Breakdown of academic impact, for papers by Silvia Park Breakdown of academic impact, for papers by U Hess Breakdown of academic impact, for papers by Cynthia Rutherford Breakdown of academic impact, for papers by Ariella Kelman Breakdown of academic impact, for papers by Vivek Kumar Breakdown of academic impact, for papers by Netanel A. Horowitz
Rankless by CCL
2026